Skip to main content
      Updated EULAR Recommendations for RA Management

      Dr. Kathryn Dao from EULAR2020 Virtual Conference

      Imaging and Remission Axial Spondyloarthritis

      Dr. Olga Petryna from EULAR2020 Virtual Conference

      OP0079 - what MRI findings are most predictive in AxSpa

      OP0314 - Drug free remission in AxSpA

      GCA and Risk of Cancer or Visual Loss

      Dr. Olga Petryna from EULAR2020 Virtual Conference

      OP0149 Tocilizumab Treats Visual Loss in GCA

      OP0143 GCA in Israel and risk of Cancer

      MSK Flares with Vedolizumab

      Dr. Rachel Tate from EULAR2020 on Abstract FRI0294

      Bimekizumab in Ankylosing Spondylitis

      Dr. Rachel Tate from EULAR2020 Virtual Conference

      Biosimilars in Spondyloarthritis

      Dr. Rachel Tate from EULAR2020 Virtual Conference 0632

      - ETN Biosimilar in Reactive Arthritis 0650

      - Treasure Study in infliximab biosimilar in SpA

      Easier Early Arthritis

      Dr. David Liew from EULAR2020 Virtual Conference

      Early Patient Referrals

      Preclinical RA patients

      Enticing New Options in ANCA-Associated Vasculitis

      Dr. David Liew from EULAR2020 ANCA-Associated Vasculitis Avacopan vs Prednisone MAINRITSAN 2 study - Calprotectin

      RT @DrPetryna: #EULAR2020 #op0054 DISCOVER 1&2 rct results for Guselkumab in PsA w/ sacroiliitis: significantly bett

      Olga Petryna DrPetryna

      5 years 4 months ago
      #EULAR2020 #op0054 DISCOVER 1&2 rct results for Guselkumab in PsA w/ sacroiliitis: significantly better BaSDAI, improved spinal pain& ASDAS-CRP vs PBO suggestive of good clincial efficacy. No radiographic data @RheumNow https://t.co/MeXV08hcBU
      RT @DrPetryna: #EULAR2020 #op0051 presence of Structural Enthrseal Lesions (SEL) in PSO associated w/higher risk of prog

      Olga Petryna DrPetryna

      5 years 4 months ago
      #EULAR2020 #op0051 presence of Structural Enthrseal Lesions (SEL) in PSO associated w/higher risk of progression to PsA: 37.5%If SEL present vs 3.4% no SEL/no arthalgia& 15.2% no SEL/+arthralgia. Highest risk in PSO w/SEL+arthralgia at 42.8% @RheumNow https://t.co/7knYXeap7l
      RT @DrPetryna: How do you approach your PsA patients with suboptimal response to MTX in moderate doses?

      Olga Petryna DrPetryna

      5 years 4 months ago
      How do you approach your PsA patients with suboptimal response to MTX in moderate doses?
      RT @DrPetryna: #EULAR2020 #op0050 RCT ph4 results: in inadequately controlled PsA addition of ADA results in better outc

      Olga Petryna DrPetryna

      5 years 4 months ago
      #EULAR2020 #op0050 RCT ph4 results: in inadequately controlled PsA addition of ADA results in better outcomes in terms MDA, ACR20, PASI75, HAQ-DI&LEI as opposed to MTX dose escalation @RheumNow https://t.co/iMgCkRawCl
      RT @DrPetryna: How does virtual EULAR make you feel? @RheumNow

      Olga Petryna DrPetryna

      5 years 4 months ago
      How does virtual EULAR make you feel? @RheumNow
      RT @DrPetryna: Not missing being torn between ballroom 1 and exhibit hall 2 😃 #EULAR2020 #onlinelearning #VirtualConf

      Olga Petryna DrPetryna

      5 years 4 months ago
      Not missing being torn between ballroom 1 and exhibit hall 2 😃 #EULAR2020 #onlinelearning #VirtualConference @RheumNow https://t.co/rHLquYPjW5
      RT @DrPetryna: #EULAR2020 #LB0001 SELECT-PsA-1 Upadacitinib vs PBO vs ADA: UPA 15/30 mg non-inferior &UPA 30 superio

      Olga Petryna DrPetryna

      5 years 4 months ago
      #EULAR2020 #LB0001 SELECT-PsA-1 Upadacitinib vs PBO vs ADA: UPA 15/30 mg non-inferior &UPA 30 superior to ADA for ACR20. At wk12 ACR 20 70.6% UPA15, 78.5% UPA30 vs 36.2%PBO & 65%ADA. Better ACR50/70 &MDA va PBO. No new safety signals. @RheumNow https://t.co/QZkMdoqXEC
      ×